drugset

drugset / Trial / NCT06782490

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 ↗

Phase 2 Recruiting 200 enrolled Celgene Corporation

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

Timeline

Start: 2025-06-05
Primary completion: 2027-05-26
Completion: 2027-06-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986368	Unknown	—	Oral

Indications